Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Landos Biopharma Inc (LABP)

Landos Biopharma Inc (LABP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,179
  • Shares Outstanding, K 40,255
  • Annual Sales, $ 18,000 K
  • Annual Income, $ -38,420 K
  • 60-Month Beta 0.96
  • Price/Sales 1.40
  • Price/Cash Flow N/A
  • Price/Book 0.49
Trade LABP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.17
  • Most Recent Earnings -0.28 on 08/11/22
  • Next Earnings Date 11/21/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.29
  • Number of Estimates 3
  • High Estimate -0.28
  • Low Estimate -0.30
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +9.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5600 +24.11%
on 10/03/22
1.1500 -39.57%
on 09/15/22
-0.1650 (-19.19%)
since 09/06/22
3-Month
0.5600 +24.11%
on 10/03/22
1.3699 -49.27%
on 08/09/22
-0.0153 (-2.15%)
since 07/06/22
52-Week
0.5501 +26.34%
on 05/25/22
15.3000 -95.46%
on 10/11/21
-14.1750 (-95.33%)
since 10/06/21

Most Recent Stories

More News
Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update

Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of...

LABP : 0.6950 (-0.71%)
The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma

Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma are part of Zacks top Analyst Blog

ANGN : 0.9401 (-5.95%)
APLT : 0.6300 (-33.68%)
LABP : 0.6950 (-0.71%)
BOLT : 1.5000 (+1.35%)
IKNA : 3.23 (-3.29%)
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

ANGN : 0.9401 (-5.95%)
APLT : 0.6300 (-33.68%)
LABP : 0.6950 (-0.71%)
BOLT : 1.5000 (+1.35%)
IKNA : 3.23 (-3.29%)
Why Encompass Health (EHC) is Down 2.4% Since Q1 Earnings Beat

Encompass Health Corporation (EHC) looks to unveil eight additional de novo locations this year and increase its bed count.

ANGN : 0.9401 (-5.95%)
ASND : 115.90 (+2.15%)
EHC : 49.05 (-1.03%)
LABP : 0.6950 (-0.71%)
Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

ANGN : 0.9401 (-5.95%)
PRGO : 38.58 (-0.64%)
APLT : 0.6300 (-33.68%)
LABP : 0.6950 (-0.71%)
Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year ...

LABP : 0.6950 (-0.71%)
Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical...

LABP : 0.6950 (-0.71%)
Should You Buy Landos Biopharma (LABP) Ahead of Earnings?

Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

LABP : 0.6950 (-0.71%)
Landos Biopharma Announces Leadership Transition

Josep Bassaganya-Riera Steps Down as Chairman, President and CEO Tim M. Mayleben Appointed Interim President and CEO Chris Garabedian Appointed...

LABP : 0.6950 (-0.71%)
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis

Phase 1 trial is underway with topline results expected in the first half of 2022 Represents Landos’ seventh IND cleared overall and the second IND...

LABP : 0.6950 (-0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Landos Biopharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. Landos Biopharma Inc. is based in BLACKSBURG, Va.

See More

Key Turning Points

3rd Resistance Point 0.7777
2nd Resistance Point 0.7539
1st Resistance Point 0.7244
Last Price 0.6950
1st Support Level 0.6711
2nd Support Level 0.6473
3rd Support Level 0.6178

See More

52-Week High 15.3000
Fibonacci 61.8% 9.6655
Fibonacci 50% 7.9251
Fibonacci 38.2% 6.1846
Last Price 0.6950
52-Week Low 0.5501

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar